Matinas Biopharma Raises $10 Million in Registered Direct Offering
Wednesday, 3 April 2024, 12:38
Matinas Biopharma Announces Successful Registered Direct Offering
Matinas BioPharma Holdings has secured $10 million in funds through a registered direct offering, involving the sale of common stock and warrants under securities purchase agreements. The proceeds from this offering are designated for working capital purposes, marking a strategic financing move for the company.
Key Highlights:
- Amount Raised: $10 million
- Purpose: Working capital
- Offering Type: Registered direct
- Impact: The funding will support Matinas Biopharma's operational needs and growth initiatives
This development underscores the company's commitment to solidifying its financial position and driving strategic progress in the pharmaceutical industry.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.